NCT06659042

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

A Prospective, Single-arm Phase II Study of the Efficacy and Safety of Tislelizumab in Combination With Chemotherapy Perioperative Treatment for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Shanghai Chest Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the perioperative study is to evaluate pathological complete response in resectable II-IIIB(N2) KRAS-mutated nonsquamous non-small cell lung cancer participants receiving tislelizumab plus platinum-based doublet chemotherapy.

Conditions

• Lung Cancer, Non-Small Cell

Interventions

Type	Name	Description
DRUG	Tislelizumab	administered via Intravenous (IV) injection
DRUG	Cisplatin	administered via IV infusion
DRUG	Carboplatin	administered via IV infusion
DRUG	Pemetrexed Disodium	administered via IV infusion

Timeline

• Start date: 2024-11-20
• Primary completion: 2025-11-20
• Completion: 2027-11-20
• First posted: 2024-10-26
• Last updated: 2025-05-18

Locations

1 site across 1 country: China